Founded in 2011 and headquartered in Kingston, Rhode Island, CREmedical is dedicated to advancing the field of neurology through innovative electroencephalography (EEG) equipment. The company's core mission is to enhance the understanding of the brain and improve the diagnosis and treatment of mental illnesses. CREmedical offers high-fidelity, high spatial resolution EEG devices that provide superior signal acquisition and unique electrical stimulation capabilities. Their products are designed for various applications, including seizure detection, biomarker discovery, event-related potentials, brain-computer interfaces, and neuromodulation.

CREmedical has made significant strides in the neurology equipment market, attracting attention from notable investors and industry experts. The company's technology is recognized for its ability to cancel muscle artifacts in real-time, providing cleaner signals for more accurate diagnoses and research outcomes. Through its pioneering work, CREmedical has had a substantial impact on both clinical practices and neuroscientific research, setting new standards in brain sensing and neuromodulation.